Literature DB >> 17600086

Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance.

Chunlin Wang1, Yumi Mitsuya, Baback Gharizadeh, Mostafa Ronaghi, Robert W Shafer.   

Abstract

The detection of mutant spectra within a population of microorganisms is critical for the management of drug-resistant infections. We performed ultra-deep pyrosequencing to detect minor sequence variants in HIV-1 protease and reverse transcriptase (RT) genes from clinical plasma samples. We estimated empirical error rates from four HIV-1 plasmid clones and used them to develop a statistical approach to distinguish authentic minor variants from sequencing errors in eight clinical samples. Ultra-deep pyrosequencing detected an average of 58 variants per sample compared with an average of eight variants per sample detected by conventional direct-PCR dideoxynucleotide sequencing. In the clinical sample with the largest number of minor sequence variants, all 60 variants present in > or =3% of genomes and 20 of 35 variants present in <3% of genomes were confirmed by limiting dilution sequencing. With appropriate analysis, ultra-deep pyrosequencing is a promising method for characterizing genetic diversity and detecting minor yet clinically relevant variants in biological samples with complex genetic populations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17600086      PMCID: PMC1933516          DOI: 10.1101/gr.6468307

Source DB:  PubMed          Journal:  Genome Res        ISSN: 1088-9051            Impact factor:   9.043


  25 in total

Review 1.  Genetic variation analyses by Pyrosequencing.

Authors:  Taimour Langaee; Mostafa Ronaghi
Journal:  Mutat Res       Date:  2005-06-03       Impact factor: 2.433

2.  Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine.

Authors:  R E Edelstein; D A Nickerson; V O Tobe; L A Manns-Arcuino; L M Frenkel
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

3.  Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms.

Authors:  M Vahey; M E Nau; S Barrick; J D Cooley; R Sawyer; A A Sleeker; P Vickerman; S Bloor; B Larder; N L Michael; S A Wegner
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

4.  Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.

Authors:  Sarah Palmer; Mary Kearney; Frank Maldarelli; Elias K Halvas; Christian J Bixby; Holly Bazmi; Diane Rock; Judith Falloon; Richard T Davey; Robin L Dewar; Julia A Metcalf; Scott Hammer; John W Mellors; John M Coffin
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

5.  Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine.

Authors:  Denise Lecossier; Nancy S Shulman; Laurence Morand-Joubert; Robert W Shafer; Véronique Joly; Andrew R Zolopa; François Clavel; Allan J Hance
Journal:  J Acquir Immune Defic Syndr       Date:  2005-01-01       Impact factor: 3.731

6.  Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma.

Authors:  R W Shafer; D J Levee; M A Winters; K L Richmond; D Huang; T C Merigan
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

7.  Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.

Authors:  Tamara Flys; Dwight V Nissley; Cassidy W Claasen; Dana Jones; Chanjuan Shi; Laura A Guay; Philippa Musoke; Francis Mmiro; Jeffrey N Strathern; J Brooks Jackson; James R Eshleman; Susan H Eshleman
Journal:  J Infect Dis       Date:  2005-06-01       Impact factor: 5.226

8.  Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.

Authors:  Jeffrey A Johnson; Jin-Fen Li; Lynn Morris; Neil Martinson; Glenda Gray; James McIntyre; Walid Heneine
Journal:  J Infect Dis       Date:  2005-06-01       Impact factor: 5.226

9.  Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.

Authors:  Gonzague Jourdain; Nicole Ngo-Giang-Huong; Sophie Le Coeur; Chureeratana Bowonwatanuwong; Pacharee Kantipong; Pranee Leechanachai; Surabhon Ariyadej; Prattana Leenasirimakul; Scott Hammer; Marc Lallemant
Journal:  N Engl J Med       Date:  2004-07-09       Impact factor: 91.245

10.  Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma.

Authors:  Giovanina M Ellis; Madhumita Mahalanabis; Ingrid A Beck; Gregory Pepper; Amy Wright; Shannon Hamilton; Sarah Holte; Willscott E Naugler; Diane M Pawluk; Chung-Chen Li; Lisa M Frenkel
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

View more
  215 in total

1.  Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants.

Authors:  Sara Gianella; Wayne Delport; Mary E Pacold; Jason A Young; Jun Yong Choi; Susan J Little; Douglas D Richman; Sergei L Kosakovsky Pond; Davey M Smith
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.

Authors:  Aaron C Logan; Hong Gao; Chunlin Wang; Bita Sahaf; Carol D Jones; Eleanor L Marshall; Ismael Buño; Randall Armstrong; Andrew Z Fire; Kenneth I Weinberg; Michael Mindrinos; James L Zehnder; Scott D Boyd; Wenzhong Xiao; Ronald W Davis; David B Miklos
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

3.  Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.

Authors:  Daniele Armenia; Ina Vandenbroucke; Lavinia Fabeni; Herwig Van Marck; Valeria Cento; Roberta D'Arrigo; Liesbeth Van Wesenbeeck; Fernanda Scopelliti; Valeria Micheli; Bianca Bruzzone; Sergio Lo Caputo; Jeroen Aerssens; Giuliano Rizzardini; Valerio Tozzi; Pasquale Narciso; Andrea Antinori; Lieven Stuyver; Carlo Federico Perno; Francesca Ceccherini-Silberstein
Journal:  J Infect Dis       Date:  2012-01-11       Impact factor: 5.226

4.  QuRe: software for viral quasispecies reconstruction from next-generation sequencing data.

Authors:  Mattia C F Prosperi; Marco Salemi
Journal:  Bioinformatics       Date:  2011-11-15       Impact factor: 6.937

5.  Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID.

Authors:  Cassandra B Jabara; Corbin D Jones; Jeffrey Roach; Jeffrey A Anderson; Ronald Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-30       Impact factor: 11.205

Review 6.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

7.  What Next? The Next Transit from Biology to Diagnostics: Next Generation Sequencing for Immunogenetics.

Authors:  Christian Gabriel; Stephanie Stabentheiner; Martin Danzer; Johannes Pröll
Journal:  Transfus Med Hemother       Date:  2011-09-25       Impact factor: 3.747

8.  Next-Generation Sequencing to Help Monitor Patients Infected with HIV: Ready for Clinical Use?

Authors:  Richard M Gibson; Christine L Schmotzer; Miguel E Quiñones-Mateu
Journal:  Curr Infect Dis Rep       Date:  2014-04       Impact factor: 3.725

9.  Rapid deep sequencing of patient-derived HIV with ion semiconductor technology.

Authors:  Max W Chang; Glenn Oliveira; Jinyun Yuan; Jason F Okulicz; Samuel Levy; Bruce E Torbett
Journal:  J Virol Methods       Date:  2013-02-04       Impact factor: 2.014

10.  Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen.

Authors:  Mariacarmela Solmone; Donatella Vincenti; Mattia Carlo Felice Prosperi; Alessandro Bruselles; Giuseppe Ippolito; Maria Rosaria Capobianchi
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.